Comparative Pharmacology
Head-to-head clinical analysis: M V C 9 3 versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V C 9 3 versus MVC PLUS.
M.V.C. 9+3 vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
M.V.C. 9+3 is a multivitamin supplement providing essential vitamins and minerals that serve as cofactors in various metabolic reactions, including energy production, DNA synthesis, and cellular function. The specific components include B-vitamins (thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, ascorbic acid) and vitamins A, D, E, and K, which act as antioxidants, support immune function, and are required for normal growth and development.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
1 vial (10 mL) intravenously over at least 30 minutes daily, or as directed by vitamin and mineral requirements.
10 mg orally once daily.
None Documented
None Documented
Variable per component: thiamine 1-2 h, pyridoxine 15-20 h, cyanocobalamin 6 days (plasma); clinical depletion: weeks to months for stores.
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Renal: 10-70% (B vitamins, ascorbic acid, electrolytes); fecal: minimal (trace unabsorbed components). Biliary: negligible.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Multivitamin
Multivitamin/Mineral Supplement